Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.

@article{Kim2016CombinationTW,
  title={Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.},
  author={U. Kim and E. Won and Seung-Jung Kee and Sook-In Jung and Hee-Chang Jang},
  journal={Antiviral therapy},
  year={2016},
  volume={21 5},
  pages={
          455-9
        }
}
Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a… Expand
154 Citations

Paper Mentions

Interventional Clinical Trial
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19  
ConditionsCOVID-19
InterventionDrug, Other
Interventional Clinical Trial
New coronavirus infection is an important cause of public health emergencies at home and abroad, which seriously affects people's health and social stability. The outbreak of SRAR… Expand
ConditionsCOVID-19, Recombinant Human Interferon α1β
InterventionDrug
Interim Guidelines on Antiviral Therapy for COVID-19
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus
...
1
2
...